CONSORT diagram. by Aina Gabarrell-Pascuet (17696594)

“…</p><p>Results</p><p>The study sample (N = 27) was mainly composed of females (74%) and the mean age was 74.26 years. 21 participants completed the intervention (22% drop-out rate). Statistically significant (<i>p</i><0.01) decreases in emotional loneliness and depressive symptoms were observed following the intervention. …”

Footprints of Pr77^Gag on the WT and LRI-III mutant packaging signal RNAs. by Suresha G. Prabhu (19797666)

“…All nucleotides that show a reactivity decrease >40% upon Gag addition, also show statistically significant difference according to the Mann–Whitney non parametrical U test (<i>p</i> < 0.05). …”

<b>Data for opposing effects</b><b> of maize straw and its biochar on soil N</b>_{<strong>2</strong>}<b>O emissions</b><b> </b><b>by mediating microbial nitrification and d... by MOULIANG XIAO (21266015)

“…However, biochar addition (5 t C ha⁻¹) reduced available N, i.e., 11.1–13.9% for NH₄⁺, 11.0–14.8% for NO₃⁻ and 13.8–16.6% WSON, and decreased the abundances of nitrification/denitrification genes (39.0–44.6% for AOB <i>amoA</i>, 29.5–35.5% for <i>nirK</i>, 24.4–31.8% for <i>nirS</i>) and associated genera <i>Nitrosospira</i>, <i>Mesorhizobium</i>, <i>Bradyrhizobium</i>, <i>Rhizobium</i>, <i>Pseudomonas</i>, and <i>Cupriavidus</i>. …”

Data used to generate Figs 1D, 3B, 3D, and 4. by Lanxin Ji (20290942)

Probe IDs for protein EpiScore. by Atchara Dawangpa (16560735)

“…A total of 41 participants were assessed at baseline, 7 weeks, and 14 weeks into the training. …”

Flow chart of study design. by Atchara Dawangpa (16560735)

“…A total of 41 participants were assessed at baseline, 7 weeks, and 14 weeks into the training. …”

Critical Role of Transcription Factor CtSR in Mediating Ergosterol Biosynthesis and DMI Fungicides Sensitivity in Colletotrichum truncatum by Wei Sun (93580)

“…Deletion of <i>CtSR</i> rendered a naturally resistant isolate highly sensitive to DMIs, significantly reduced total ergosterol levels, decreased <i>CYP51s</i> expression compared to the wild type, and abolished DMI-induced expression of <i>CYP51s</i>. …”

Critical Role of Transcription Factor CtSR in Mediating Ergosterol Biosynthesis and DMI Fungicides Sensitivity in Colletotrichum truncatum by Wei Sun (93580)

“…Deletion of <i>CtSR</i> rendered a naturally resistant isolate highly sensitive to DMIs, significantly reduced total ergosterol levels, decreased <i>CYP51s</i> expression compared to the wild type, and abolished DMI-induced expression of <i>CYP51s</i>. …”

Cortical and subcortical regions feature distinct early and late responses during audition. by Sarah H. McGill (22505225)

“…The mean no-stimulus trial spectrograms were subtracted from the mean maximum-intensity trial spectrograms, and a cluster-based permutation testing was employed to identify significant differences between the conditions (p < 0.05, 5000 iterations). …”

Sex- and age-related changes in individual variance and behavioural repeatability. by Andréa L. Johnson (22505376)

Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”